Group items tagged

"The affirmation that the omega-3 DHA can benefit cognitive and eye health offers hope to previously rejected claims. And it's business as usual regarding the overall health claims process, despite ratification of the Lisbon Treaty, said a European Commission representative. At the NutraIngredients Health Claims 2010 conference in Brussels, the EC's Lars Korsholm explained the regulatory state-of-play for DHA claims. "I think it will offer some hope to previously rejected claims in the sense that these claims that are now subject for discussion are generic in the sense that if other food business operators than those who actually submitted the application can claim to fulfill the conditions of use then they are equally entitled to use the claim," explains Korsholm. The statements come in relation to an October decision whereby the European Food Safety Authority (EFSA) affirmed that the omega-3 fatty acids, DHA and ALA, can benefit eye and cognitive development in babies. Responding to the public comment period for Merck Selbstmedikation GmbH's article 14 cognitive development claim that was rejected in March, EFSA affirmed its original stance that there was no need for additional supplementation of DHA (docosahexaenoic acid) and ALA (alpha-linolenic acid) because it already existed at adequate levels in the diet. It supported their role in foetal and newborn eye and brain development but said there was an adequate supply in breast milk. "

"Orlando, FL - Adding extended-release niacin (Niaspan, Abbott) to statin therapy results in a significant regression of atherosclerosis as measured by carotid intima-media thickness (IMT), whereas the addition of ezetimibe (Zetia, Merck/Schering-Plough) to statin therapy did not, according to an eagerly anticipated study "